Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study assessing Senstend in China

Next Previous
X
Search
Trial Profile

A study assessing Senstend in China

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine/prilocaine (Primary)
  • Indications Premature ejaculation
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Dec 2020 New trial record
    • 17 Nov 2020 According to a Regent Pacific media release, an amount of US$3.20 million (HK$24.96 million) will be received upon the receipt of the approval from the NMPA to conduct this study.
    • 17 Nov 2020 According to a Regent Pacific media release, the investigational new drug (IND) for Clinical Trial Approval (CTA) has been submitted to the Center of Drug Evaluation of the National Medical Products Administration by Wanbang Pharmaceutical in China to seek marketing approval of Senstend in China. The approval is expected in by the end of Q1 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top